SLP

[kslifka]

I've been getting alot of stocks from the AMEX on my screener lately.

SLP might be a good catch at the 9ema.  Nice steady high volume.  It's up 100% in the past month.

[njshiva]

Nice find kslifka. 

[kslifka]

Still waiting to get into this one.  Volume remains strong for SLP.

Wait till 9ema.

[njshiva]

 IBD Top-Rated Stocks Under $10  update

"Simulations Plus  (SLP) surged higher for the eighth straight week. Earnings growth has been in triple-digit territory for three consecutive quarters. The software maker will announce earnings on Tuesday, Jan. 16."

[kslifka]

Here is another stock that keeps walking the 9ema.

Are we afraid of profits...

[la-onda]

what a beautiful chart 
applause

Top 5 Pharmaceutical Company Signs Five-Year Extension of Services Agreement with Simulations Plus
Monday February 12, 9:15 am ET
Contract Signals Long-Term Demand for Simulations Plus' Software and Consulting Services

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (AMEX:SLP - News), a leading provider of software for pharmaceutical discovery and development, today announced that a top 5 pharmaceutical company has signed a five-year extension to a master services agreement with Simulations Plus.

Ron Creeley, vice president of marketing and sales for Simulations Plus, said: "This contract extension adds to an agreement signed two years ago to provide consulting and software training services on demand for this large pharmaceutical customer. Although revenues from this agreement are expected to be modest in comparison to our software sales to this client, we believe that the agreement demonstrates the demand for our expertise in training for users of our software and consulting services. This company, whose name I can't reveal because of contractual obligations, seeks assistance from Simulations Plus' scientists when they're faced with particularly difficult projects involving complex oral absorption/pharmacokinetics during preclinical and clinical development."

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: "This customer is one of the largest pharmaceutical companies in the world, and was not only one of our earliest GastroPlus(TM) software customers but, in fact, was the source of our first study contract about eight years ago. Our close relationships and collaborations with the scientists in this customer's U.S. and European R&D sites have helped us to better meet their needs and to advance the state-of-the-art of our software. The fact that this agreement has been renewed and extended for a longer period than the previous agreements is a clear indication of the confidence and satisfaction placed in Simulations Plus scientists to provide valued assistance in software training and consulting activities."

[la-onda]

fyi:
Simulations Plus boosts revenue forecast
Monday February 26, 5:52 pm ET
Simulations Plus Boosts 2007 Revenue View to $7.85 Million, Up $2 Million From 2006 Revenue

LANCASTER, Calif. (AP) -- Simulations Plus Inc., a maker of drug development software, said it boosted its revenue forecast for fiscal year 2007 to $7.85 million.

Chairman and Chief Executive Walt Woltosz told shareholders at the annual meeting Friday that the new target represents a $2 million increase over 2006 revenue. The company said it had originally projected a $1 million increase over last year. Woltosz also told shareholders the company's application for a $100,000 National Institutes of Health small business grant appeared favorable. A decision on the application is expected in June.
Also at the meeting, shareholders re-elected the existing board, ratified the company's selection of auditors and approved the 2007 stock option plan, according to a statement issued by the company Monday..

Shares closed up 5 cents at $8.81 on the American Stock Exchange.

[la-onda]

updated chart

[la-onda]

Taglich Brothers quotation:

Key Investment Considerations:
We are maintaining coverage of Simulations Plus, Inc. (AMEX: SLP) with a Speculative Buy recommendation and increasing our twelve-month price target to $10.80 per share from our prior price target of $8.15 per share. The increase in our price target is due to the growth prospects we anticipate for fiscal 2007 and 2008.
On February 26, 2007, SLP updated fiscal 2007 net sales guidance at its annual shareholders meeting. Management is estimating that fiscal 2007 top line results should increase by at least $2.0 million versus fiscal 2006 results, reaching approximately $7.850 million for the twelve month period ending August 31, 2007. On February 12, 2007, Simulations Plus announced that a top five pharmaceutical company signed a five-year extension to a master services agreement. This is a contract extension that adds to an agreement signed two
years ago. Based on updated public guidance from Management for fiscal 2007 and current licensing trends and renewals, we are adjusting our forecasts for fiscal 2007. Our net sales and net income forecasts are $7.846 million and $1.571 million or $0.18 per diluted share, respectively. Our prior forecasts called for net sales and net income of $7.241 million and $1.311 million or $0.15 per diluted share, respectively.
We are adjusting our estimates for fiscal 2008. Given current licensing trends, renewals, and potential for new customers, our revised net sales and net income forecasts are $9.695 million and $2.405 million or $0.28 per diluted share. Our prior forecasts called for net sales and net income of $8.270 million and $1.950 million or $0.23 per diluted share.

[la-onda]

please don´t ask me why I didn´t bought SLP.
Positive analysis but didn´t trigger the buy button 

[la-onda]

awesome 
Simulations Plus Reports Second Quarter FY2007 Financial Results
Tuesday April 10, 9:15 am ET
First Six Months' Revenues up 73% and Earnings Jump 1384%

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (AMEX:SLP - News), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported preliminary financial results for the second quarter of its 2007 fiscal year (2Q07) ended February 28, 2007.

Ms. Momoko Beran, chief financial officer of Simulations Plus, stated: "Consolidated revenues for 2Q07 set a new record for any quarter at $2,534,000, an increase of 71% from $1,482,000 in the second quarter of fiscal year 2006 (2Q06). The previous quarterly record (4Q03) of about $2,100,000 included a 3-year contract for $1,200,000 that was booked up front. We now book revenues ratably over the life of the license/contract by billing our customers annually, so 2Q07 revenues are based only on revenues earned within 12 months. Revenues from pharmaceutical software and services were up 105% to $1,808,000 from $884,000 in 2Q06. Revenues for our Words+ subsidiary for 2Q07 increased 21.4%, to $726,000 from $598,000 in 2Q06. Consolidated gross profit increased 80.6% to $1,977,000 in 2Q07 from $1,095,000 in 2Q06. R&D expense increased 80.8% to $216,000 in 2Q07 from $120,000 in 2Q06, primarily due to expansions within our Life Sciences staff. Consolidated SG&A increased 36.1% to $936,000 in 2Q07, compared to $688,000 in 2Q06; however, as a percentage of sales, SG&A decreased from 46.4% to 36.9%. Major expense increases were selling expenses, such as commissions to dealers and trade shows, as well as printer/copier rental, salaries, and payroll-related expenses such as health insurance and payroll taxes, which outweighed decreases in professional fees.

"Net income before taxes for 2Q07 increased 185% to $856,000 from $300,000 in 2Q06. Second quarter earnings were impacted by a provision for income taxes of $188,000 that will not actually be paid, but rather will be a write-off from our deferred tax asset. EBITDA increased 148% for the second quarter to $1,120,000 or $0.12 per fully diluted share, as compared with $451,000 or $0.06 per fully diluted share for the second quarter of FY2006. Consolidated net earnings for the quarter increased 169% over last year's second quarter to $668,000, or $0.07 per diluted share based on 9,014,825 shares, as compared to $248,000, or $0.03 per diluted share for 2Q06, based on 8,180,450 split-adjusted shares. Thus, earnings per share increased by 144%, as compared to the analyst's estimate of 67%, even with the increase in number of fully diluted shares of over 10%. Cash increased by $1,534,000 to approximately $3,219,000 during the first six months of FY07."

Ms. Beran continued: "For the first six months of FY2007, consolidated revenues set a new six-month record at $3,990,000, an increase of $1,690,000 or 73.4% from $2,301,000 in the first six months of FY2006. Revenues from pharmaceutical software and services were up 143% to $2,632,000 from $1,083,000 in 2Q06. Revenues for our Words+ subsidiary increased 11.5% in the first six months, to $1,358,000 from $1218,000. In the first six months, consolidated gross profit increased 89.1% to $2,992,000 from $1,582,000; R&D expense increased 84.4% to $400,000 from $217,000, primarily due to expansions within our Life Sciences staff, and SG&A increased 28.6% to $1,693,000, compared to $1,316,000; however, as a percentage of sales, SG&A decreased from 57.2% to 42.4%. Major expense increases were for the same reasons described above for the second quarter.

"Net income before taxes for the first six months of FY2007 increased 1498% to $950,000 from $59,000. The first six months' earnings were impacted by a provision for income taxes of $209,000 that will not actually be paid, but rather will be a write-off from our deferred tax asset. Consolidated net earnings increased by 1384% to $741,000, or $0.08 per diluted share based on 8,812,656 shares, as compared to $50,000, or $0.01, based on 8,107,420 split-adjusted shares in the first six months of FY2006. Shareholders' equity at the end of the first six months was $6,607,000, an increase of 16.5% from $5,669,000 at the beginning of the fiscal year."

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: "To say that we're pleased to report these results is an understatement. Halfway through the year, revenues are already about $1.7 million ahead of last year. This is most of the estimated increase of $2 million revenues for the entire year that we provided in our latest guidance. We plan to update our guidance after the end of the third quarter. Our cash position is excellent and we continue to be debt-free. We're seeking acquisition opportunities, and we're usually in discussions with one or more potential candidates; however, there can be no assurances that we'll proceed with any of them. We have just submitted a second $100,000/6-month Phase I Small Business Innovation Research proposal to the National Institutes of Health, and we're told that the outstanding review we received on the $100,000/6-month proposal we submitted in December means it is very likely to be funded in June, but of course, there are no guarantees."

Woltosz continued: "Clearly, the excitement level is high at Simulations Plus, and the recognition we've received both in the industry and in the stock market over the last four months is satisfying. Recent scientific publications by both universities and our customers attest to the industry-leading position we enjoy with our major software products. We continue to believe that we are in a period of growing recognition on the part of the pharmaceutical industry that software tools like those provided by Simulations Plus are not a luxury; rather, they are an absolute necessity that repay their investment quickly and many times over."

[la-onda]

Simulations Plus on FIRE today 
(again I have missed the entry  )
cheers
O.

[kslifka]

Simulations Plus on FIRE today 
(again I have missed the entry  )
cheers
O.

Funny...I was the one that started this thread and I never bought.

Great bullish engulfing candlestick pattern.

[la-onda]

fyi:

On April 10, 2006, Simulations Plus reported results for its second quarter of 2007, ended February 28, 2007.
SLP reported revenues of $2.534 million and net income of $0.668 million or $0.07 per diluted share. In 2Q06, the Company reported revenues of $1.095 million and net income of $0.248 million or $0.03 per diluted share.
In comparison, Taglich Brothers' estimates called for revenues of $1.875 million and net income of $0.395 million or $0.05 per diluted share.

http://www.taglichbrothers.com/equityuniverse/companies/simplus/simplus.asp

[la-onda]

quotation again from 10th of April:

Woltosz continued: "Clearly, the excitement level is high at Simulations Plus, and the recognition we've received both in the industry and in the stock market over the last four months is satisfying. Recent scientific publications by both universities and our customers attest to the industry-leading position we enjoy with our major software products. We continue to believe that we are in a period of growing recognition on the part of the pharmaceutical industry that software tools like those provided by Simulations Plus are not a luxury; rather, they are an absolute necessity that repay their investment quickly and many times over."
updated chart: